Company news
Basilea Pharmaceutica Ag (SIX:BSLN) news
Every Basilea Pharmaceutica Ag press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
August 5, 2026
Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix
July 29, 2026
Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
May 28, 2026
Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting
April 15, 2026
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
April 9, 2026
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
March 23, 2026
Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
February 25, 2026
Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance
February 17, 2026
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
February 9, 2026
Basilea joins INCATE to support antifungal innovation
January 13, 2026
Basilea provides portfolio update and outlook
January 8, 2026
Basilea and Prokaryotics enter collaboration to develop a novel broad-spectrum antifungal for the treatment of severe invasive infections
January 7, 2026
Prokaryotics and Basilea enter collaboration to develop a novel broad-spectrum antifungal for severe invasive infections
January 7, 2026
Phare Bio and Basilea Announce Landmark Partnership to Develop Next-Generation Broad-Spectrum Antibiotic Using AI
December 11, 2025
Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a...
December 11, 2025
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea
November 4, 2025
Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam
September 25, 2025
Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
September 16, 2025
Basilea on track with strong 2025 half-year results
August 19, 2025
Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic
August 14, 2025
Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold infections
July 29, 2025
Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
July 8, 2025
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea
June 5, 2025
Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States
May 20, 2025
Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea
April 24, 2025
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
April 16, 2025
Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025
April 16, 2025
Basilea reports strong 2024 full-year results with significant increase in revenue, profit and operating cash flow
February 18, 2025